A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Completed · Phase 3 · NCT06649045
Conditions: OSA, Overweight or Obesity
At a glance
- Research payments reported, 2025
- $6.0M
- U.S. investigators named
- 20
- Sites paid
- 19
- Planned or actual enrollment
- 712
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Orforglipron (drug), Placebo (drug)
- Dates
- Started 2024-10-22; completion 2026-07-30
- Results posted
- Not yet
Study GZRA is a master protocol that will support 2 independent studies, GZ01 and GZ02. Participants will be assigned to the appropriate study prior to randomization. The purpose of the studies is to evaluate the efficacy and safety of orforglipron in participants who have moderate-to-severe OSA and obesity or overweight. Study GZ01 will include participants who are unable or are unwilling to use PAP therapy. Study GZ02 will include participants who are on PAP therapy for at least 3 months at time of screening and plan to continue PAP therapy during the study.
From ClinicalTrials.gov, last updated 2026-09-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $6.0M in research payments for this study in 2025 (43 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Stacey L. Layle, MD Family Medicine · San Diego, CA
- Lawrence D. Sher, M.D. Pediatrics · Rolling Hills Estates, CA
- Apinya B. Vutikullird, D.O. Family Medicine · Cypress, CA
- Mauricio L. Waintrub, M.D. Internal Medicine · Aurora, CO
- Aliu O. Sanni, MD Specialist · Loganville, GA
- Gary W. Soucie, MD Family Medicine · Blackfoot, ID
- Diana T. Widicus, MD Family Medicine · Rochester, IL
- James P. Maynard, M.D. Neurology · Fort Thomas, KY
- David S. Green, M.D. Specialist · Shreveport, LA
- John C. Parker, M.D. Endocrinology & Diabetes · Wilmington, NC
- Kisria Rechul, M.D. Obesity Medicine · Albuquerque, NM
- Robert E. Dunn, MD Cardiac Electrophysiology · Cleveland, OH
- Paul Hartley, M.D. Internal Medicine · Uniontown, PA
- Bryce Palchick, M.D. Family Medicine · Pittsburgh, PA
- Mary B. Riley, D.O. Internal Medicine · Uniontown, PA
- Felix O. Berglund, MD Cardiology · Nashville, TN
- Wasim A. Haque, M.D. Endocrinology & Diabetes · Flower Mound, TX
- John D. Hudson, M.D. Sleep Medicine · Austin, TX
- Gaylon Kipp, MD Family Medicine · Bellevue, WA
- Nazia H. Rahman, M.D. Pediatrics · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Futuresearch Trials of Neurology LP $882,496
- Preferred Primary Care Physicians Inc $729,697
- Ark Clinical Research LLC $649,993
- Care Access Research LLC $555,773
- Northwest Clinical Research Center $545,312
- Peninsula Headlands LLC $487,260
- N Texas Diabetes and Endocrine $418,868
- Cti Holdings Inc DBA Community Research Management Associates Inc $391,130
- Artemis Headlands LLC $344,080
- Ebgs Clinical Research Center Snellville $335,327
- Maimonides Sleep Arts and Siences DBA the Sleep Spot Maimonides $320,415
- Elite Clinical Trials Lllp $234,483
- Piedmont Medical Research Associates Inc $67,344
- Prairie Education and Research Coop $12,650
- $2,048
- Rheumatology Center of Houston $570
- Palos Verdes Medical Group $90
- Cleveland Clinic, OH $66
- Future Search Trials of Dallas LP $60
- Cti-Crc $54
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.